Drug class in one race
HMG-CoA reductase / NPC1L1 drugs for Atherosclerotic Cardiovascular Disease
4 tracked HMG-CoA reductase / NPC1L1 drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the HMG-CoA reductase / NPC1L1 page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
2 Phase 32 preclinical / unstaged
Head-to-head evidence: AG2304R vs Atozet (ezetimibe/atorvastatin) · AG2304R vs MK0653A, ezetimibe (+) simvastatin · AG2304R vs Rosuvamibe · Atozet (ezetimibe/atorvastatin) vs MK0653A, ezetimibe (+) simvastatin · MK0653A, ezetimibe (+) simvastatin vs Rosuvamibe